Who Paid My Doc
A Multicentre Randomized, Double-Blind, Placebo-Controlled, Dose-Findi
Research payments
$5,268,639
Through program year 2025, $5,268,639 in research payments was reported against A Multicentre Randomized, Double-Blind, Placebo-Controlled, Dose-Findi, across 564 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $293,166 | 174 |
| 2024 | Research | $4,740,525 | 345 |
| 2023 | Research | $234,948 | 45 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Rawan Jumean Miami, FL Named on 116 payments
- Eddie Armas Miami, FL Named on 85 payments
- James Wild Irving, NY Named on 38 payments
- Harold Bays Louisville, KY Named on 38 payments
- Mark Jaffe Hollywood, FL Named on 31 payments
- Rafael Chiong Wong Miami, FL Named on 30 payments
- George Walker New Orleans, LA Named on 30 payments
- Vikas Sayal Las Vegas, NV Named on 25 payments
- Thomas Klein Wichita, KS Named on 22 payments
- Francisco Badar Cerritos, CA Named on 21 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.